PDA

View Full Version : Mesoblast Ltd.



  1. Key Pharmaceutical Executive Joins Mesoblast
  2. Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
  3. Mesoblast Reports Strong Half-Year Financial Results
  4. Key European Patent Granted for Mesoblast's MPCs
  5. Boardroom Radio Interview with Mesoblast Chief Executive
  6. Mesoblast limited Lowered to "Hold" at Morningstar (MSB)
  7. Positive Disc Repair Results Using Mesoblast Stem Cells
  8. Mesoblast limited Stock Rating Lowered by Morningstar (MSB)
  9. Stem Cell Meeting on the Mesa - Oct 2013 - Video
  10. Mesoblast limited Downgraded to "Hold" at Morningstar (MSB)
  11. 3 Companies Banking on Regenerative Medicine
  12. BREEDI : BREEDIT CORP. FILES (8-K/A) Disclosing Unregistered Sale of Equity ...
  13. Osiris Therapeutics, Inc. : Osiris Therapeutics Updates on Mesoblast Payment ...
  14. Mesoblast announces positive results from phase II trial of MPCs to treat type ...
  15. Mesoblast Reports Positive Type 2 Diabetes Trial Results
  16. Mesoblast Reports Positive Type 2 Diabetes Trial Results
  17. Mesoblast Limited (MSB.AX) Reports Positive Type 2 Diabetes Trial Results
  18. Mesoblast limited : New Japanese Regenerative Medicine Legislation
  19. Mesoblast fast tracked to enter Japanese market with their stem cell products
  20. Mesoblast limited : Scrip Award to Mesoblast for 2013 Financing Deal of the Year
  21. MPCs Strengthen Cardiac Function in End-Stage Heart Failure
  22. Chairman's Address to Shareholders
  23. Mesoblast limited : Improved Survival in Children with GvHD After Cell Therapy
  24. Mesoblast limited : MPCs Induce Functional Recovery in Ischemic Stroke Model
  25. Mesoblast limited : FDA Clears Phase 3 Heart Failure Trial
  26. FDA Clears Commencement of Phase 3 Chronic Heart Failure Trial Using Mesoblast Limited (MSB.AX)'s Proprietary Cells
  27. MESOBLAST LIMITED : Mesoblast, Intrexon and Ziopharm to Target Cancers
  28. MESOBLAST LIMITED : MSBs Registration Plans for GVHD Cell Product in Japan
  29. Mesoblast, Intrexon and Ziopharm to Target Cancers
  30. Mesoblast Limited (MSB.AX), Intrexon Corporation and ZIOPHARM Oncology, Inc. (ZIOP.OB) to Target Cancers
  31. Mesoblast limited (ADR) (MBLTY.PK): Mesoblast: Prochymal Deal Controversy ...
  32. Mesoblast limited (ADR) (MBLTY.PK): Mesoblast: Prochymal Deal Controversy ...
  33. Mesoblast limited (ADR) (MBLTY.PK): Mesoblast: Prochymal Deal Controversy ...
  34. MESOBLAST LIMITED : Mesoblast Acquires Osiris' Cultured Stem Cell Business
  35. Osiris Announces Agreement for Culture-Expanded MSCs Including Prochymal Worth Up To $100 Million Plus Royalties
  36. MESOBLAST LIMITED : Spinal Fusion Trial to be Presented at Premier Spine ...
  37. MESOBLAST LIMITED : Share Trading Policy
  38. MESOBLAST LIMITED : Share Trading Policy
  39. Strong Cash Position Enables Execution of Late-Stage Trials
  40. Strong Cash Position Enables Execution of Late-Stage Trials
  41. Midday: ASX up, gold miners shine
  42. Midday: ASX boosted by Fortescue, China PMI
  43. Midday: ASX boosted by Fortescue, China PMI
  44. Midday: ASX dips, earnings flow & dividends drag
  45. Midday: ASX dips, earnings flow & dividends drag
  46. Midday: Mixed messages freeze ASX flat
  47. Midday: Mixed messages freeze ASX flat
  48. MSB Receives $4.3M Pipeline Funds from Australian Government
  49. MSB Receives $4.3M Pipeline Funds from Australian Government
  50. Mesoblast Wins $3.9M in Australian Tax Credits Tied to Mesenchymal Precursor Cells
  51. MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
  52. MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
  53. Key Mesenchymal Precursor Cell Patent Granted in Japan
  54. MESOBLAST LIMITED : 15 May 2013 - Mesoblast's Preclinical Trial Results of ...
  55. Mesoblast Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and ...
  56. MESOBLAST LIMITED : 15 May 2013 - Mesoblast's Preclinical Trial Results of ...
  57. MESOBLAST LIMITED : 17 April 2013 – Mesoblast Appoints Renowned ...
  58. MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
  59. MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
  60. MESOBLAST LIMITED : 12 April 2013 - Mesoblast Chief Executive Honoured at ...
  61. MESOBLAST LIMITED : 13 March 2013 - Mesoblast Completes A$170m Private ...
  62. MESOBLAST LIMITED : 13 March 2013 - Mesoblast Completes A$170m Private ...
  63. MESOBLAST LIMITED : 11 February 2013 - Mesoblast Reports Half-Year 2013 ...
  64. FDA Agree on Use of MSBs Singapore Manufacturing Facility
  65. Mesoblast Limited (ASX: MSB) (OTC ADR: MBLTY) Earnings and Development ...
  66. Mesoblast Limited (ASX: MSB) (USOTC: MBLTY) Key Mesenchymal Precursor ...
  67. Mesoblast, patents and China
  68. Mesoblast limited
  69. FDA Clears Phase 2 Clinical Trial for Rheumatoid Arthritis
  70. FDA Clears Phase 2 Clinical Trial for Rheumatoid Arthritis
  71. Positive Results in Phase 2 Lumbar Spinal Fusion Trial
  72. MESOBLAST LIMITED : 13 December 2012 - Blood Cell Expansion Trial in New ...
  73. Mesoblast Corporate Overview - CEO Message to AGM
  74. MESOBLAST LIMITED : 20 November 2012 - Mesoblast Reaches Key ...
  75. MESOBLAST LIMITED : 19 November 2012 – Market Update
  76. Mesoblast Ltd Completes Acquisition Of Angioblast Systems Inc; Announces Shares Placement; Cephalon, Inc. Acquires Shareholding In Mesoblast Ltd
  77. Nobel Winner's Stem Cells to Be Tested in Eye Malady in 2013
  78. Analyst quick to defend honour of biopharma Mesoblast
  79. Australian Stock Market Report – Midday 9/25/2012
  80. A biotech bonanza may be just hype
  81. Rexahn Reports Positive Phase 2 Data for Archexin; Dynavax Announces FDA ...
  82. World Leader in Regenerative Medicine to Be Among Companies Attending ...
  83. Cellmid appoints Graeme Kaufman as non executive director
  84. Cellmid appoints Graeme Kaufman as non executive director
  85. Mesoblast stem cell R&D spend triples
  86. Chandler Macleod posts 45pc proft rise
  87. Chandler Macleod posts 45pc proft rise
  88. Bankable asset CBA posts record profit but warns of cloudy outlook
  89. Australia's two-decade expansion at risk, McKinsey report warns
  90. Companies struggling with Facebook and Twitter backlash
  91. Health is a very good asset
  92. Commercial property values slump to lows
  93. Market big wigs face the music
  94. Country Road to take over Witchery
  95. The Short Report
  96. Midday: Aus shares 0.3% higher
  97. Midday: ASX lifts from lows on CPI
  98. RegMed sector is starting to heat up on the Hot Tin Roof
  99. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains ...
  100. Biotechs undo gains from last quarter
  101. Mesoblast Interview: The Best Adult Stem Cell Technology In The World?
  102. Australian shares flat ahead of BoE, ECB
  103. Australian shares flat ahead of BoE, ECB
  104. Outlook: ASX set to follow positive leads
  105. QRxPharma product approval hits hurdle
  106. Property performance this financial year
  107. Market Wrap: ASX up 0.7%
  108. Market Wrap: Aus shares close 0.4% lower
  109. The Short Report
  110. Midday: Aus shares fall on global fears
  111. The investor's guide to surviving a sharemarket crash
  112. The investor's guide to surviving a sharemarket crash
  113. The investor's guide to surviving a sharemarket crash
  114. NBN Co chooses Leighton, Service Stream
  115. Market Wrap: Aus shares close 1.1% lower
  116. 3 ASX stocks that beat the market yesterday
  117. Mesoblast insists Teva partnership is strong
  118. Market Wrap: ASX rises 0.4%
  119. ASX Market Wrap: ASX finishes the week on a positive note
  120. BHP lowers sights as commodity price forecasts dip in medium term
  121. The Short Report
  122. Mesoblast Provides Corporate Strategy For Product Development To Treat ...
  123. Crawling through the tape to see what's working … not much!
  124. New Teva Representative Joins Mesoblast Board of Directors
  125. FDA Petition
  126. Teva Representative Joins Mesoblast's Board of Directors
  127. New Teva Representative Joins Mesoblast Board of Directors
  128. Mesoblast limited : Msb asx new director - 10 may 2012
  129. Australian Stock Market Report – Midday 5/2/2012
  130. Australian Stock Market Report – Midday 5/2/2012
  131. Three questions to answer before the market plunges
  132. Mesoblast hits 50% enrolment for back pain trial
  133. Australian Stock Market Report – Afternoon 4/19/2012
  134. Australian Stock Market Report – Midday 4/18/2012
  135. Australian Stock Market Report – Midday 4/18/2012
  136. Intervertebral Disc Repair Phase 2 Trial Update
  137. ASX healthcare companies rebound in 2012: Acrux, ResMed, Mesoblast
  138. Athersys (ATHX) Secures New GvHD Patent for MultiStem
  139. iSonea expands board expertise with new director appointments
  140. iSonea expands board expertise with new director appointments
  141. iSonea expands board expertise with new director appointments
  142. Mesoblast Update to Credit Suisse Asia Investment Conference
  143. FDA Clears Mesoblast Ltd For Advanced Trials Of Back Pain Treatment-DJ
  144. Arizona Pain Specialists conducts pain study
  145. Market Wrap: ASX posts third weekly loss
  146. Half Year Results - Mesoblast Posts Strong Cash Balance
  147. IG Markets - Afternoon thoughts 27/2/12
  148. Mesoblast Ltd Enters Into Strategic Alliance With Lonza Group Ltd
  149. Mesoblast Ltd Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks
  150. Mesoblast Ltd Not To Pay FY 2011 Final Dividend
  151. First Minimally-Invasive Procedure Performed In Mesoblast Ltd's Phase 2 Stem Cell Trial For Lumbar Disc Repair
  152. Mesoblast Ltd Receives FDA Clearance For Phase 3 Bone Marrow Transplant Trial
  153. Mesoblast Ltd Receives FDA Approval For Bone Marrow Transplant Trial-DJ
  154. Positive Outcome from FDA Meeting
  155. Mesoblast posts successful results from diabetes stem cell trial
  156. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
  157. Mesoblast receives clearance
  158. Phase 2 Stem Cell Trial for Lumbar Disc Repair
  159. Presentation in Special Session of American Heart Association Annual Conference
  160. Mesoblast Receives FDA Clearance
  161. Mesoblast (ASX:MSB) Success in recent heart trials
  162. Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
  163. Teva buying Cephalon for $6.8 billion

Content Relevant URLs by vBSEO 3.6.0 PL2